Stichting European Myeloma Network
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Stichting European Myeloma Network sits in the upper half of US sponsors by registered trial count (#7,390 of 15,751 sponsors by registered trial count).
Stichting European Myeloma Network: 1 sponsored US clinical trial, none currently recruiting.
Stichting European Myeloma Network sponsors 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 1 trials.
Mid-pack sponsor footprint
Stichting European Myeloma Network is in the upper half of sponsors by trial count (#7,390 of 15,751 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Indexed trials (enrollment closed)
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Therapeutic Areas
How the Stichting European Myeloma Network archive is shaped
1 indexed studies, none listed as recruiting (0% open).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Multiple Myeloma (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.